Cole Douglas G.
Known title: DirectorCIK: 0001486373
Associated companies
Transaction History
| DNLI | ▲ Buy | Grant | 4,216 | $0 | 6/1/2023 | View on chart |
| DNLI | ▲ Buy | Grant | 5,986 | $0 | 6/2/2022 | View on chart |
| DNLI | ▲ Buy | Grant | 4,216 | $0 | 6/1/2023 | View on chart |
| DNLI | ▲ Buy | Grant | 5,986 | $0 | 6/2/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Denali Therapeutics Shares Test Fair Value Amid Pullback
Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.
Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.